apalutamide
Selected indexed studies
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. (N Engl J Med, 2019) [PMID:31150574]
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. (J Clin Oncol, 2021) [PMID:33914595]
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. (N Engl J Med, 2018) [PMID:29420164]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study. (2025) pubmed
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. (2019) pubmed
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. (2021) pubmed
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. (2018) pubmed
- Apalutamide. (2012) pubmed
- Apalutamide and Overall Survival in Prostate Cancer. (2021) pubmed
- Apalutamide for prostate cancer. (2019) pubmed
- Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer. (2025) pubmed
- Apalutamide: First Global Approval. (2018) pubmed
- Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. (2019) pubmed